Ann: Quarterly Business Update and Appendix 4C, page-26

Just a reminder. BD1 have progressed.

Perth, Australia, 18 May 2018: BARD1 Life Sciences Limited (ASX:BD1),

A biotechnology company developing non-invasive cancer diagnostics, has entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test system using ProcartaPlex® Technology for BARD1’s research and evaluation.The agreement defines the development of a multiplex immunoassay in kit format for the semi- quantitative detection of autoantibodies against 20 BARD1 peptides using the ProcartaPlex® Technology for performance on Luminex® instrumentation for BARD1’s research and evaluation.

The scope of work includes the transfer of the current BARD1 assay design to Thermo Fisher for optimisation of an autoantibody assay using the ProcartaPlex® Technology for BARD1’s research use.

The first application of the ProcartaPlex® Technology is to the BARD1-Ovarian test that BARD1 plans to develop for detection of ovarian cancer.

The custom research assay development project will commence on May-18 and is expected to take approximately nine months, with deliverables including Assay Feasibility Report, Development Report, Protocol, Standard Operating Procedures, Assay Validation Report, BARD1-autoantibody kits for research and evaluation, and transfer documentation.

If the development project is successful, BARD1 and Thermo Fisher will then discuss the potential for Thermo Fisher to supply research autoantibody kits to BARD1 for its use in research studies.